#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	19	17414	16S	1529	1529	100.0	16S.l6.c4.ctg.1	2214	783.6	1	SNP	n	C1184T	0	.	.	1184	1184	C	1524	1524	C	1050	C	972	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	31536	23S	2890	2890	99.9	23S.l6.c30.ctg.1	3550	885.4	0	.	n	.	0	T695C	SNP	695	695	T	1036	1036	C	928	C,T	871,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	31536	23S	2890	2890	99.9	23S.l6.c30.ctg.1	3550	885.4	0	.	n	.	0	G1337A	SNP	1337	1337	G	1678	1678	A	1121	A,G	1057,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	31536	23S	2890	2890	99.9	23S.l6.c30.ctg.1	3550	885.4	0	.	n	.	0	T1971C	SNP	1971	1971	T	2312	2312	C	1039	C	951	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	31536	23S	2890	2890	99.9	23S.l6.c30.ctg.1	3550	885.4	1	SNP	n	A2045G	0	.	.	2045	2045	A	2386	2386	A	1021	A,T	960,1	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	31536	23S	2890	2890	99.9	23S.l6.c30.ctg.1	3550	885.4	1	SNP	n	C2597T	0	.	.	2597	2597	C	2938	2938	C	988	C	935	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_P_01364c	folP.WHO_P_01364c	1	1	27	2400	folP	852	852	100.0	folP.l6.c30.ctg.1	1443	165.4	1	SNP	p	R228S	1	.	.	682	684	AGC	961	963	AGC	223;225;225	A;G;C	208;210;210	folP.WHO_P_01364c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5910	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3490	168.7	1	SNP	p	S91F	0	.	.	271	273	TCC	594	596	TCC	191;188;190	T;C,T;C	169;168,1;166	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5910	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3490	168.7	1	SNP	p	D95N	0	.	.	283	285	GAC	606	608	GAC	198;196;196	G;A,G;C	182;174,2;179	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5910	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3490	168.7	1	SNP	p	D95G	0	.	.	283	285	GAC	606	608	GAC	198;196;196	G;A,G;C	182;174,2;179	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_V_01454	mtrR.WHO_V_01454	1	1	539	1774	mtrR	633	633	99.21	mtrR.l15.c17.ctg.1	1296	136.1	0	.	p	.	0	A39T	NONSYN	115	117	GCC	449	451	ACC	195;197;195	A;C;C,A	177;185;182,1	.	.
mtrR.WHO_V_01454	mtrR.WHO_V_01454	1	1	539	1774	mtrR	633	633	99.21	mtrR.l15.c17.ctg.1	1296	136.1	0	.	p	.	0	R44H	NONSYN	130	132	CGC	464	466	CAC	199;200;199	C;A;C	188;182;188	.	.
mtrR.WHO_V_01454	mtrR.WHO_V_01454	1	1	539	1774	mtrR	633	633	99.21	mtrR.l15.c17.ctg.1	1296	136.1	0	.	p	.	0	Y105H	NONSYN	313	315	TAC	647	649	CAC	272;270;269	C;A;C,G	255;250;250,1	.	.
mtrR.WHO_V_01454	mtrR.WHO_V_01454	1	1	539	1774	mtrR	633	633	99.21	mtrR.l15.c17.ctg.1	1296	136.1	1	SNP	p	G45D	0	.	.	133	135	GGC	467	469	GGC	203;203;204	G;G;C	192;190;194	mtrR.WHO_V_01454:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	19	1012	mtrR_promoter	250	250	100.0	mtrR_promoter.l15.c17.ctg.1	1035	97.3	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	6178	parC	2304	2304	100.0	parC.l15.c30.ctg.1	2987	205.9	1	SNP	p	D86N	0	.	.	256	258	GAC	625	627	GAC	251;255;257	G;A;C	234;234;241	parC.WHO_P_00203c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	6178	parC	2304	2304	100.0	parC.l15.c30.ctg.1	2987	205.9	1	SNP	p	S87R	0	.	.	259	261	AGT	628	630	AGT	259;258;258	A;G;T	242;238;240	parC.WHO_P_00203c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	6178	parC	2304	2304	100.0	parC.l15.c30.ctg.1	2987	205.9	1	SNP	p	S87I	0	.	.	259	261	AGT	628	630	AGT	259;258;258	A;G;T	242;238;240	parC.WHO_P_00203c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	6178	parC	2304	2304	100.0	parC.l15.c30.ctg.1	2987	205.9	1	SNP	p	S87W	0	.	.	259	261	AGT	628	630	AGT	259;258;258	A;G;T	242;238;240	parC.WHO_P_00203c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	6178	parC	2304	2304	100.0	parC.l15.c30.ctg.1	2987	205.9	1	SNP	p	S88P	0	.	.	262	264	TCC	631	633	TCC	258;259;256	T;C;C	240;240;240	parC.WHO_P_00203c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	5010	parE	1986	1986	99.95	parE.l15.c4.ctg.1	2606	191.3	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1554	1556	GGC	246;241;240	G;G;C	230;225;222	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.2.001	penA.2.001	1	1	27	4460	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2309	192.1	1	SNP	p	A311V	0	.	.	931	933	GCA	1219	1221	GCA	232;230;236	G;C;A	221;216;225	penA.2.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4460	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2309	192.1	1	SNP	p	I312M	0	.	.	934	936	ATC	1222	1224	ATC	237;237;237	A;T;C	228;226;230	penA.2.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4460	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2309	192.1	1	SNP	p	V316P	0	.	.	946	948	GTG	1234	1236	GTG	235;236;237	G;T;G	228;228;228	penA.2.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4460	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2309	192.1	1	SNP	p	V316T	0	.	.	946	948	GTG	1234	1236	GTG	235;236;237	G;T;G	228;228;228	penA.2.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4460	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2309	192.1	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1738	1740	ACC	198;196;198	A;C,T;C	186;187,1;187	penA.2.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4460	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2309	192.1	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1792	1794	GCG	203;202;200	G;C;G	181;165;174	penA.2.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4460	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2309	192.1	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1792	1794	GCG	203;202;200	G;C;G	181;165;174	penA.2.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4460	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2309	192.1	1	SNP	p	G543S	0	.	.	1627	1629	GGC	1915	1917	GGC	164;164;161	G;G;C	148;149;145	penA.2.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4460	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2309	192.1	1	SNP	p	G546S	0	.	.	1636	1638	GGC	1924	1926	GGC	167;167;166	G;G;C	151;150;147	penA.2.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4460	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2309	192.1	1	SNP	p	P552S	0	.	.	1654	1656	CCG	1942	1944	CCG	152;155;154	C,G;CG,CGGG;G	119,5;114,1;118	penA.2.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	6454	ponA	2397	2397	99.96	ponA.l15.c4.ctg.1	3164	203.3	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2634	porA	1146	1146	99.83	porA.l6.c30.ctg.1	1792	146.1	0	.	p	.	0	M83fs	FSHIFT	247	247	A	568	568	C	202	C	185	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	3088	porB1b	1041	1041	97.13	porB1b.l6.c4.ctg.1	1530	200.4	0	.	p	.	0	E48G	NONSYN	142	144	GAA	417	419	GGA	282;286;286	G;G;A	268;269;264	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	3088	porB1b	1041	1041	97.13	porB1b.l6.c4.ctg.1	1530	200.4	0	.	p	.	0	T89S	NONSYN	265	267	ACC	540	542	AGC	259;258;265	A;G;C	236;235;240	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	3088	porB1b	1041	1041	97.13	porB1b.l6.c4.ctg.1	1530	200.4	0	.	p	.	0	K120D	NONSYN	358	360	AAG	633	635	GAC	239;238;239	G;A;C	222;220;219	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	3088	porB1b	1041	1041	97.13	porB1b.l6.c4.ctg.1	1530	200.4	0	.	p	.	0	A142V	NONSYN	424	426	GCC	699	701	GTC	235;238;238	G;T;C	224;221;225	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	3088	porB1b	1041	1041	97.13	porB1b.l6.c4.ctg.1	1530	200.4	0	.	p	.	0	E145G	NONSYN	433	435	GAA	708	710	GGA	239;239;240	G;G;A	228;225;225	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	3088	porB1b	1041	1041	97.13	porB1b.l6.c4.ctg.1	1530	200.4	0	.	p	.	0	V151A	NONSYN	451	453	GTA	726	728	GCA	237;240;245	G,A;C;A	225,1;226;228	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	3088	porB1b	1041	1041	97.13	porB1b.l6.c4.ctg.1	1530	200.4	0	.	p	.	0	Y212H	NONSYN	634	636	TAT	909	911	CAT	266;264;263	C;A;T	250;246;244	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	3088	porB1b	1041	1041	97.13	porB1b.l6.c4.ctg.1	1530	200.4	0	.	p	.	0	T213L	NONSYN	637	639	ACA	912	914	TTA	266;263;260	T;T;A	249;247;242	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	3088	porB1b	1041	1041	97.13	porB1b.l6.c4.ctg.1	1530	200.4	0	.	p	.	0	A244V	NONSYN	730	732	GCA	1005	1007	GTA	251;250;248	G;T,C;A	226;223,1;223	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	3088	porB1b	1041	1041	97.13	porB1b.l6.c4.ctg.1	1530	200.4	0	.	p	.	0	G253Q	NONSYN	757	759	GGA	1032	1034	CAA	237;237;237	C,T,A;A;A	219,1,1;223;224	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	3088	porB1b	1041	1041	97.13	porB1b.l6.c4.ctg.1	1530	200.4	0	.	p	.	0	.	INDELS	760	762	ACA	1036	1040	ATCAA	237;235;236;235;237	A;T;C;A;A	224;225;227;227;229	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	3088	porB1b	1041	1041	97.13	porB1b.l6.c4.ctg.1	1530	200.4	0	.	p	.	0	.	INDELS	763	764	TG	1043	1045	AGT	229;228;231	A;G;T	223;221;221	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	3088	porB1b	1041	1041	97.13	porB1b.l6.c4.ctg.1	1530	200.4	0	.	p	.	0	A257D	NONSYN	769	771	GCT	1050	1052	GAT	247;248;249	G;A;T	237;239;239	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	3088	porB1b	1041	1041	97.13	porB1b.l6.c4.ctg.1	1530	200.4	0	.	p	.	0	V270A	NONSYN	808	810	GTA	1089	1091	GCG	247;246;242	G;C;G	236;238;237	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	3088	porB1b	1041	1041	97.13	porB1b.l6.c4.ctg.1	1530	200.4	0	.	p	.	0	D293S	NONSYN	877	879	GAT	1158	1160	AGT	233;227;230	A;G;T	220;214;215	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	3088	porB1b	1041	1041	97.13	porB1b.l6.c4.ctg.1	1530	200.4	1	SNP	p	A121D	1	.	.	361	363	GAC	636	638	GAC	240;241;238	G;A;C	219;221;221	porB1b.WHO_M_02204c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	3088	porB1b	1041	1041	97.13	porB1b.l6.c4.ctg.1	1530	200.4	1	SNP	p	D121N	0	.	.	361	363	GAC	636	638	GAC	240;241;238	G;A;C	219;221;221	porB1b.WHO_M_02204c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	11704	rpoB	4179	4179	100.0	rpoB.l6.c4.ctg.1	5059	230.8	1	SNP	p	H553N	1	.	.	1657	1659	AAT	2130	2132	AAT	257;253;254	A,C;A;T	246,2;243;246	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1286	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1137	112.7	1	SNP	p	V57M	1	.	.	169	171	ATG	621	623	ATG	262;260;258	A;T;G	239;238;233	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
